Abstinent Valeant might enable Allergan deal
High on life
A slugfest between the acquisitive pharma group and its reluctant $50 bln-plus quarry will probably drag out for months. Wrangling over a shareholder meeting is one big issue. Meanwhile, Valeant will have produced results less muddled by M&A. These could be the deciding factor.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.